First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charu Aggarwal, Andrew Haas, Sarah W. Gordon, Ranee Mehra, Peter M Lee, Christine M. Bestvina, Fabien Maldonado, Vamsidhar Velcheti, Roy S. Herbst, Susan D. Bell, Rachael Gillmor, Andrea Manzanera, Christopher Jon Matheny, Estuardo Aguilar-Cordova, Laura K. Aguilar, Francesca Barone, Paul Peter Tak, Daniel Sterman
Institutions: University of Pennsylvania, University of Maryland, Baltimore, Hunter Holmes McGuire VA Medical Center, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Vanderbilt University Medical Center, Cleveland Clinic, Yale University, The Ohio State University, Candel Therapeutics (United States), GlaxoSmithKline (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281999030